Alcon announced new investigator-initiated clinical data in which Systane Pro Preservative-Free (PF) provided clinically comparable dry eye symptom relief to perfluorohexyloctane ophthalmic solution (Miebo; Bausch + Lomb). This result met the study's primary endpoint of noninferiority at both 2 weeks and 1 month based on Ocular Surface Disease Index (OSDI) scores.1,* The findings were presented at the American Academy of Optometry 2026 Annual Meeting in Anaheim, California.
The head-to-head prospective, randomized, double-masked, multicenter clinical study evaluated 256 dry eye patients with moderate to severe symptoms.1 Patients were randomized to Systane Pro PF or perfluorohexyloctane 4 times daily in both eyes and were assessed at baseline, 2 weeks, and 1 month.1 The primary endpoint evaluated noninferiority of Systane Pro PF vs perfluorohexyloctane on OSDI symptom scores and used a prespecified noninferiority margin of 7.3 units.1
Systane Pro PF demonstrated clinically meaningful dry eye symptom relief and was noninferior to perfluorohexyloctane.1,* Both treatment groups achieved statistically significant and clinically meaningful reductions in OSDI symptoms (P≤0.001) at 2 weeks that were sustained through 1 month.1,*
Systane Pro PF is available over the counter (OTC) in the United States, Canada, and other markets. Miebo is available by prescription in the US, while perfluorohexyloctane is offered OTC in certain markets outside of the US.
*Based on a prospective, randomized, controlled, double-masked, multicenter noninferiority clinical trial comparing mean change in OSDI scores from baseline at 2 weeks and 1 month. Between-group difference was -2.7 at 2 weeks and -3.0 at 1 month, P=0.004 and P=0.01, respectively. QID dosing. N=256.
1. Alcon data on file, 2026. REF-30545.